Results 91 to 100 of about 1,785 (194)

Antimicrobial consumption and resistance in bacteria from humans and food‐producing animals

EFSA Journal, Volume 22, Issue 2, February 2024.
Abstract The fourth joint inter‐agency report on integrated analysis of antimicrobial consumption (AMC) and the occurrence of antimicrobial resistance (AMR) in bacteria from humans and food‐producing animals (JIACRA) addressed data obtained by the Agencies' EU‐wide surveillance networks for 2019–2021.
European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA)   +2 more
wiley   +1 more source

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants

The Journal of Clinical Pharmacology, 2016
AbstractOmadacycline is a first‐in‐class aminomethylcycline antibiotic being evaluated in phase 3 studies as oral and intravenous monotherapy for bacterial infections. This was a phase 1, randomized, open‐label, 4‐period, crossover study that evaluated the effect of food consumption on the bioavailability of omadacycline.
Tzanis, Evan, Manley, Amy, Villano, Stephen, Tanaka, S. Ken, Bai, Stephen, Loh, Evan   +5 more
openaire   +2 more sources

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens

, 2018
Omadacycline, a first-in-class aminomethylcycline antibiotic, is related to tetracyclines but is structurally modified to circumvent mechanisms of resistance to tetracyclines.
Stephen Bai, Stephen Villano, Surya Chitra, Lynne Garrity-Ryan, Amy Manley, Lu Ann Bundrant, Evan Tzanis   +6 more
core   +1 more source

Pharmacokinetics, Distribution, Metabolism and Excretion of Omadacycline Following a Single Intravenous or Oral Dose of 14C-omadacycline in Rats

, 2017
The pharmacokinetics, absorption, distribution, metabolism and excretion of Omadacycline, a first in class aminomethylcycline antibiotic with a broad spectrum of activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria, were ...
Lin, Wen, He, Handan, Mangold, James, Flarakos, Jimmy, Du, Yancy   +4 more
core  

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Clinical Pharmacokinetics
Omadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dose, single-arm study was conducted to characterize the pharmacokinetic (PK) profile of omadacycline in people with CF ...
Madeline Sanders, Eunjin Hong, Peter S. Chung, Adupa P. Rao, Paul Beringer   +4 more
openaire   +2 more sources

In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)

Journal of Global Antimicrobial Resistance
Objectives: Omadacycline is an aminomethylcycline (tetracycline class) antibacterial approved by the United States Food and Drug Administration (2018) for treatment of adults with acute bacterial skin and skin structure infection (ABSSSI) and community ...
Michael D. Huband, Paul R. Rhomberg, Kelley A. Fedler, Christopher Blankers, Diane Anastasiou, Alisa W. Serio, Mariana Castanheira   +6 more
doaj   +1 more source

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

, 2017
Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation.
Robert K. Flamm, Michael A. Pfaller, Michael D. Huband, Paul R. Rhomberg   +3 more
core   +1 more source

Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial and distal human colon [PDF]

, 2019
A clinically reflective model of the human colon was used to investigate the effects of the broad-spectrum antibiotic omadacycline on the gut microbiome, and subsequent potential to induce simulated Clostridium difficile infection (CDI).
Ewin, D, Chilton, CH, Buckley, AM, Wilcox, MH, Moura, IB, Shearman, S, Clark, E   +6 more
core   +1 more source

Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results from an Open-Label, Non- Inferiority, Randomized Controlled Trial [PDF]

Background The incidence of bone and joint infections (BJIs) continues to increase, and existing oral BJI antibiotics have limitations. Omadacycline may be a potential treatment option for BJI treatment due to activity against doxycycline-resistant S ...
Romo-Kozan, Vanessa, Flores, Evelyn A., Kang, Amy Y., Miller, Loren G., Tran, Donna Phan, Delgado, Guarina Garcia, Payan, Isabel   +6 more
core   +1 more source

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

, 2018
Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC 50
Robert K. Flamm, Michael A. Pfaller, Michael D. Huband, Dee Shortridge   +3 more
core   +1 more source